Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2585095 | 0.82 | ALDH1A1 (0.55) | LMNAKMT2ARAB9AHPGDNPC1 | |
| SCHEMBL2580961 | 0.81 | ALDH1A1 (0.65) | LMNARAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4263699 | 0.79 | MAPT (0.60) | LMNAKMT2ARAB9AHPGDNPC1 | |
| SCHEMBL4267373 | 0.77 | ALDH1A1 (0.53) | LMNAKMT2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2588184 | 0.76 | MAPT (0.63) | LMNAKMT2ARAB9AHPGDNPC1 | |
| SCHEMBL2584766 | 0.74 | KMT2A (0.44) | LMNAKMT2ARAB9AHPGDNPC1 | |
| SCHEMBL13545783 | 0.73 | KMT2A (1.00) | LMNAKMT2ARAB9AHPGDNPC1 | |
| SCHEMBL2580660 | 0.72 | ALDH1A1 (0.60) | LMNAKMT2ARAB9AHPGDNPC1 | |
| SCHEMBL2579076 | 0.71 | GAA (0.55) | LMNAKMT2ARAB9AHPGDNPC1 | |
| SCHEMBL14140710 | 0.71 | ALDH1A1 (0.98) | LMNAKMT2ARAB9AHPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | claimed |
| EP-1869053-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-ISOXAZOLO[4,5-C]PYRIDINE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2007-12-26 | — | — | EP | claimed |
| WO-2006105945-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-ISOXAZOLO[4,5-C]PYRIDINE COMPOUNDS AND THEIR USE IN THE PRODUCTION OF MEDICAMENTS | Grünenthal GmbH (DE) | 2006-10-12 | — | — | WO | claimed |
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | GRUENENTHAL GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076001-A1 | Substituted 4,5,6,7 -Tetrahydro-Isoxazolo[4,5-C]Pyridine Compounds and Use Thereof for Producing Medicaments | P2RX5, P2RX4, P2RX7 | LMNA 2302/4885KMT2A 4073/4885RAB9A 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.